A monovalent anti-human CD28 domain antibody antagonist: Preclinical efficacy and safety

Journal of Immunology

Volumn 191, Issue 9, 2013, Pages 4599-4610

  Suchard, Suzanne J ^a   Davis, Patricia M ^a   Kansal, Selena ^a   Stetsko, Dawn K ^a   Brosius, Ruth ^a   Tamura, James ^a   Schneeweis, Lumelle ^a   Bryson, James ^a   Salcedo, Theodora ^a   Wang, Haiqing ^a   Yang, Zheng ^a   Fleener, Catherine A ^a   Ignatovich, Olga ^b   Plummer, Christopher ^b   Grant, Steven ^b   Nadler, Steven G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIMITOTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD28 DOMAIN ANTIBODY 001; CD28 DOMAIN ANTIBODY 002; CD28 RECEPTOR; CD86 ANTIGEN; CELL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG; ANTIBODY; CTLA4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CTLA-4 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; T-LYMPHOCYTES;

EID: 84886035929     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300470     Document Type: Article

References (47)

1. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. G. Emerson, J. M. Leiden, and C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86: 1333-1337.
2. Sperling, A. I., J. A. Auger, B. D. Ehst, I. C. Rulifson, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157: 3909-3917.
3. Linsley, P. S., and S. G. Nadler. 2009. The clinical utility of inhibiting CD28mediated costimulation. Immunol. Rev. 229: 307-321.
4. Larsen, C. P., T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi, E. Strobert, D. Anderson, S. Cowan, K. Price, J. Naemura, et al. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5: 443-453.
5. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kündig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261: 609612.
6. Tada, Y., K. Nagasawa, A. Ho, F. Morito, O. Ushiyama, N. Suzuki, H. Ohta, and T W. Mak. 1999. CD28-deficient mice are highly resistant to collagen-induced arthritis. J. Immunol. 162: 203-208.
7. Ogawa, S., K. Nitta, Y Hara, S. Horita, H. Nihei, and R. Abe. 2000. CD28 knockout mice as a useful clue to examine the pathogenesis of chronic graftversus-host reaction. Kidney Int. 58: 2215-2220.
8. Girvin, A. M., M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164: 136-143.
9. Zhu, Y, H. Ljunggren, E. Mix, H. L. Li, P. van der Meide, A. M. Elhassan, B. Winblad, and J. Zhu. 2001. CD28-B7 costimulation: a critical role for initiation and development of experimental autoimmune neuritis in C57BL/6 mice. J. Neuroimmunol. 114: 114-121.
10. Tada, Y, K. Nagasawa, A. Ho, F. Morito, S. Koarada, O. Ushiyama, N. Suzuki, A. Ohta, and T. W. Mak. 1999. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J. Immunol. 163: 3153-3159.
11. Webb, L. M., M. J. Walmsley, and M. Feldmann. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26: 2320-2328.
12. Knoerzer, D. B., R. W. Karr, B. D. Schwartz, and L. J. Mengle-Gaw. 1995. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 96: 987-993.
13. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227.
14. Chu, E. B., M. V. Hobbs, C. B. Wilson, C. G. Romball, P. S. Linsley, and W. O. Weigle. 1996. Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J. Immunol. 156: 1262-1268.
15. Racke, M. K., D. E. Scott, L. Quigley, G S. Gray, R. Abe, C. H. June, and P. J. Perrin. 1995. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96: 21952203.
16. Perrin, P. J., C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke. 1999. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 163: 1704-1710.
17. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
18. Rudd, C. E., A. Taylor, and H. Schneider. 2009. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229: 12-26.
19. Wing, K., Y Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T Nomura, and S. Sakaguchi. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
20. Poirier, N, A. M. Azimzadeh, T. Zhang, N. Dilek, C. Mary, B. Nguyen, X. Tillou, G. Wu, K. Reneaudin, J. Hervouet, et al. 2010. Inducing CTLA-4dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2: 17ra10.
21. Zhang, T., S. Fresnay, E. Welty, N. Sangrampurkar, E. Rybak, H. Zhou, X. F Cheng, Q. Feng, C. Avon, A. Laaris, et al. 2011. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4dependent manner. Am. J. Transplant. 11: 1599-1609.
22. Poirier, N., C. Mary, N. Dilek, J. Hervouet, D. Minault, G. Blancho, and B. Vanhove. 2012. Preclinical efficacy and immunological safety of FR104, an antagonist antiCD28 monovalent Fab' antibody. Am. J. Transplant. 12: 2630-2640.
23. McKinnon, M., Nadler, S. G, Suchard, S. J., Classon, B., Holmes, S., Ignatovich, O., Plummer, C, Grant, S. 2010. Compositions monovalent for CD28 binding and methods of use. Patent US 8454959-B2 25 04-JUN-2013. Available at: http://getentry.ddbj.nig.ac.jp/getentry/na/HJ186739-HJ208592/?filetype= html&limit=100. Accessed August 29, 2013.
24. H and Vk domain antibodies. Methods Mol. Biol. 911: 39-63.
25. McCafferty, J., A. D. Griffiths, G. Winter, and D. J. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554.
26. Holt, L. J., A. Basran, K. Jones, J. Chorlton, L. S. Jespers, N. D. Brewis, and I. M. Tomlinson. 2008. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21: 283-288.
27. Davis, P. M., S. G. Nadler, D. K. Stetsko, and S. J. Suchard. 2008. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin. Immunol. 126: 38-47.
28. Lühder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Müller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hünig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.
29. Stebbings, R., L. Findlay, C. Edwards, D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, et al. 2007. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179: 3325-3331.
30. Winter, G., A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12: 433-455.
31. Fishburn, C. S. 2008. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97: 4167-4183.
32. Yao, S., Y. Zhu, G. Zhu, M. Augustine, L. Zheng, D. J. Goode, M. Broadwater, W. Ruff, S. Flies, H. Xu, et al. 2011. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34: 729-740.
33. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1: 793-801.
34. Findlay, L., G. Sharp, B. Fox, C. Ball, C. J. Robinson, C. Bird, R. Stebbings, D. Eastwood, M. Wadhwa, S. Poole, et al. 2011. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 55: 141-151.
35. Wing, K., and S. Sakaguchi. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11: 7-13.
36. Villinger, F., P. Bostik, A. Mayne, C. L. King, C. P. Genain, W. R. Weiss, and A. A. Ansari. 2001. Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. Immunogenetics 53: 315-328.
37. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
38. Horvath, C. J., and M. N. Milton. 2009. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event? Toxicol. Pathol. 37: 372-383.
39. Vincenti, F. 2008. Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 121: 299-306; quiz 307-308.
40. Vanhove, B., G. Laflamme, F. Coulon, M. Mougin, P. Vusio, F. Haspot, J. Tiollier, and J. P. Soulillou. 2003. Selective blockade of CD28 and not CTLA4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 102: 564-570.
41. Holliger, P., and P. J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23: 1126-1136.
42. Chames, P., M. Van Regenmortel, E. Weiss, and D. Baty. 2009. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157: 220-233.
43. Eastwood, D., L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161: 512-526.
44. Stebbings, R., D. Eastwood, S. Poole, and R. Thorpe. 2013. After TGN1412: recent developments in cytokine release assays. J. Immunotoxicol. 10: 75-82.
45. Ball, C., B. Fox, S. Hufton, G. Sharp, S. Poole, R. Stebbings, D. Eastwood, L. Findlay, P. W. Parren, R. Thorpe, et al. 2012. Antibody C region influences TGN1412-like functional activity in vitro. J. Immunol. 189: 5831-5840.
46. 2005. TGN1412 Investigator's Brochure. TeGenero Immunotherapeutics, Wurzburg, Germany.
47. (-/-) mice. Blood 108: 238-245.